Email: [email protected]

1988 B.S., University of Bombay, India

1. Signoretti, C., Matsumura, S., D'silva, M., et al. (2026). Glucose-6-phosphate dehydrogenase variants modify 3D genomic organization to suppress maladaptive and vascular disease. Journal of Biological Chemistry, 302(8), Article 113204.
2. Signoretti, C., Matsumura, S., Doja, J., et al. (2026). VEGFR-2 blocker induces pulmonary vascular disease in rats with CRISPR-edited human non-deficient G6PD polymorphism: role of 3D genomic modifications and DNA methylation. British Journal of Pharmacology, 183(16), 4675–4697.
3. D'silva, M., Jackson, K., Vaughan, M. T., et al. (2026). 12-Lipoxygenase (12-LOX) plays a key role in the hyperinflammatory response caused by SARS-CoV-2. mBio, 17(6), Article e00738-26.
4. Signoretti, C., Fatehi, S., Drewes, R., et al. (2026). Bleomycin-induced lung fibrosis and dysfunction is exacerbated by G6PD deficiency. American Journal of Physiology-Lung Cellular and Molecular Physiology, 330(2), L145–L158.
5. Signoretti, C., Matsumura, S., Fatehi, S., et al. (2024). G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease. Journal of the American Heart Association, 13(19), Article e035174.
6. Wojciak-Stothard, B., Gupte, S., & Bossone, E. (2024). Disease mechanisms and therapeutic targets in pulmonary hypertension: Key insights from the special issue of vascular pharmacology on pulmonary hypertension. Vascular Pharmacology, 156, Article 107415.
7. Matsumura, S., Signoretti, C., Fatehi, S., et al. (2024). Loss-of-function G6PD variant moderated high-fat diet-induced obesity, adipocyte hypertrophy, and fatty liver in male rats. Journal of Biological Chemistry, 300(7), Article 107460.
8. Krajnik, A., Nimmer, E., Brazzo, J. A., III, et al. (2023). Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells. APL Bioengineering, 7(4), Article 046104.
9. Signoretti, C., & Gupte, S. A. (2023). G6PD Orchestrates Genome-Wide DNA Methylation and Gene Expression in the Vascular Wall. International Journal of Molecular Sciences, 24(23), Article 16727.
10. D'Addario, C. A., Matsumura, S., Kitagawa, A., et al. (2023). Global and endothelial G-protein coupled receptor 75 (GPR75) knockout relaxes pulmonary artery and mitigates hypoxia-induced pulmonary hypertension. Vascular Pharmacology, 153, Article 107235.
11. Gupte, S. A., Bakshi, C. S., Blackham, E., et al. (2023). The severity of SARS-CoV-2 infection in K18-hACE2 mice is attenuated by a novel steroid-derivative in a gender-specific manner. British Journal of Pharmacology, 180(20), 2677–2693.
12. Signoretti, C., Matsumura, S., Fatehi, S., & Gupte, S. (2023). Insight into the increased risk associated with CRISPR-generated African G6PD variant (N126D) in rat model of sugen-5416-induced pulmonary hypertension. Physiology, 38(S1).
13. Jacob, C., Kitagawa, A., Signoretti, C., et al. (2022). Mediterranean G6PD variant mitigates expression of DNA methyltransferases and right heart pressure in experimental model of pulmonary hypertension. Journal of Biological Chemistry, 298(12), Article 102691.
14. Matsumura, S., D'Addiaro, C., Slivano, O. J., et al. (2022). Mediterranean G6PD variant rats are protected from Angiotensin II-induced hypertension and kidney damage, but not from inflammation and arterial stiffness. Vascular Pharmacology, 145, Article 107002.
15. Hashimoto, R., & Gupte, S. A. (2022). G6PD is a critical enabler of hypoxia-induced accumulation of macrophages and platelets in mice lungs and contributor to lung inflammation. Vascular Pharmacology, 144, Article 106976.
16. Agostinucci, K., Hutcheson, R., Hossain, S., et al. (2022). Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase. Journal of Hypertension, 40(3), 498–511.
17. D'Addario, C., Kitagawa, A., Matsumura, S., et al. (2022). Deletion Of G-Protein-Coupled Receptor 75 Prevents Hypoxia-Induced Pulmonary Vasoconstriction and Hypertension. The FASEB Journal, 36(S1).
18. Stier, C. T., Jr., & Gupte, S. (2021). Commentary on Expression of Exogenous Epithelial Sodium Channel Beta Subunit in the Mouse Middle Cerebral Artery Increases Pressure-Induced Constriction COMMENT. American Journal of Hypertension, 34(11), 1143–1144.
19. Kitagawa, A., Jacob, C., Jordan, A., et al. (2021). Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor plus Hypoxia. Journal of Pharmacology and Experimental Therapeutics, 377(2), 284–292.
20. Dhagia, V., Kitagawa, A., Jacob, C., et al. (2021). G6PD activity contributes to the regulation of histone acetylation and gene expression in smooth muscle cells and to the pathogenesis of vascular diseases. American Journal of Physiology-Heart and Circulatory Physiology, 320(3), H999–H1016.
21. Kitagawa, A., Kizub, I., Jacob, C., et al. (2020). CRISPR-Mediated Single Nucleotide Polymorphism Modeling in Rats Reveals Insight Into Reduced Cardiovascular Risk Associated With Mediterranean G6PD Variant. Hypertension, 76(2), 523–532.
22. Gupte, R., Dhagia, V., Rocic, P., et al. (2020). Glucose-6-phosphate dehydrogenase increases Ca2+ currents by interacting with Cav1.2 and reducing intrinsic inactivation of the L-type calcium channel. American Journal of Physiology-Heart and Circulatory Physiology, 319(1), H144–H158.

Profile Details
https://www.nymc.edu/gsbms/about/leadership/program-directors/gupte-sachin-a.php?utm
https://scholar.google.com/citations?user=z_WCkPoAAAAJ&hl=en
https://www.researchgate.net/scientific-contributions/Sachin-A-Gupte-38473048

WOS ResearcherID: FYP-3572-2022